GlobalData on MSN11mon
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depression
The transcranial magnetic stimulation (TMS) device is cleared for use as an adjunct treatment in patients aged 15-21 years ...
Hosted on MSN11mon
FDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
This approval marks NeuroStar as the first and only transcranial magnetic stimulation (TMS) therapy cleared by the FDA for use in this younger demographic, expanding its indications to a fourth ...
manilatimes1mon
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
These publications further cement NeuroStar's position as the leader in advancing TMS therapy and shaping the future of depression treatment.” The following publications highlight key findings about ...
Morningstar15d
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
In addition to selling the NeuroStar system and associated treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”) operates treatment centers across the United States, offering ...